TOTAL Antibody recognized Anti-Idiotypic Antibody Discovery Service

Overview Service Published Data Service Highlight FAQ

At Creative Biolabs, we offer a specialized anti-idiotypic antibody production service designed to detect the total amount of your antibody drug. Leveraging our advanced platforms and extensive experience, we deliver high-quality, non-inhibitory anti-idiotypic antibodies (anti-ID Abs). These crucial reagents provide unparalleled insights into your drug's true concentration and immunogenicity profile, empowering your biotherapeutic development.

Overview of Antigen Non-Blocking Anti-Idiotypic Antibodies

The unique variable region of an antibody, known as its idiotype, is a critical determinant of its function and specificity. Anti-ID Abs are precisely engineered antibodies capable of recognizing and specifically binding to these idiotypes. As meticulously prepared reagents, anti-ID Abs are indispensable tools for reference in anti-drug antibody (ADA) detection, playing a pivotal role in comprehensive immunogenicity analysis. Furthermore, their distinct specific binding epitopes enable their utilization for accurately measuring the concentration of antibody drugs within biological fluids, which is crucial for robust pharmacokinetic (PK) analysis of these vital therapeutics. Based on their interaction with the antibody drug's antigen-binding site, anti-ID Abs are broadly categorized into antigen-blocking, antigen-non-blocking, and drug-target complex types.

Fig. 1 Anti-idiotypic antibody types. (Creative Biolabs Original) Fig. 1 Types of anti-idiotypic antibody.

Antigen non-blocking anti-ID Abs are valuable tools because they recognize unique sites on the antibody drug located outside its complementary, antigen-binding region. This distinct binding mechanism ensures that this type of antibody can simultaneously bind to the antibody drug alongside its target antigen without any mutual interference, making them ideal for detecting the total amount of antibody drugs present in a sample. This non-inhibitory characteristic provides assay developers with enhanced flexibility and delivers more comprehensive information regarding the availability and functional state of the drug antibody in complex biological matrices. Such reagents are essential for a complete understanding of drug exposure in vivo.

Our Service

Creative Biolabs' total antibody recognized anti-ID Ab discovery service is meticulously designed to meet the rigorous demands of biotherapeutic development. We employ a sophisticated competitive selection approach utilizing cutting-edge phage display techniques to isolate anti-ID Abs that specifically detect total antibody levels. Our specialized selection strategies are engineered to ensure the generation of antibodies that bind to an idiotope located precisely outside the antibody drug's antigen-binding site. This guarantees a non-inhibitory binding mode, providing you with highly specific and functionally superior reagents for your critical PK and ADA assays.

Antigen non-blocking anti-ID antibodies' properties:

Not paratope specific
Not inhibitory
Detects total antibody (free, partially bound, fully bound)

Interaction pattern of anti-idiotypic antibody identifying the complete antibody. (Creative Biolabs Original) Fig.2 Binding mode of anti-idiotypic antibody detecting total antibody.

Please click here to see more custom Anti-Idiotypic Antibodies Production Services from Creative Biolabs to meet your specific requirements.

Published Data

Serological testing dogs for opisthorchiasis by indirect-ELISA using anti-idiotypic antibodies. Fig.3 Detection of canine opisthorchiasis via indirect ELISA utilizing anti-idiotypic antibodies.¹

A monoclonal antibody targeting a specific epitope on the excretory-secretory antigen protein of Opisthorchis felineus was employed in a sandwich ELISA to immobilize the liver fluke-specific antigen on a solid phase. When human sera were analyzed, the epitope revealed by this monoclonal antibody showed significant relevance within the parasite protein, as validated against commercial tests. Using a hybridoma technique, an anti-idiotypic antibody mimicking this epitope was produced, capable of binding the specific antibody and inducing an immune response. Infected dogs' serum samples demonstrated that the anti-idiotypic antibody effectively replaced the liver fluke antigen in both indirect and competitive ELISAs, providing reliable opisthorchiasis diagnosis without the need for parasite antigen or experimental animals.

Service Highlight

Comprehensive Total Drug Detection

Our anti-ID Abs are meticulously designed to recognize free, partially bound, and fully bound forms of your therapeutic, offering a complete picture of drug exposure.

Superior Specificity and Low Cross-Reactivity

Through rigorous competitive screening and counter-selection, we ensure our anti-IDs exhibit exceptional specificity for your antibody drug with minimal interference from endogenous human immunoglobulins.

Optimized for PK and ADA Assays

The non-inhibitory nature of our anti-IDs makes them ideal for developing highly accurate and sensitive PK and ADA assays, critical for regulatory submissions.

Tailored for Complex Biologics

We adapt our discovery workflows to accommodate the unique structural complexities of various biotherapeutic modalities, including bispecifics and antibody-drug conjugates (ADCs).

High Affinity and Stability

We prioritize the generation of anti-ID Abs with robust binding affinities and excellent long-term stability, ensuring reliable and consistent performance in your critical assays over time.

Assay-Ready Reagents

Our comprehensive characterization ensures that the anti-ID Abs delivered are immediately suitable for integration into your bioanalytical assays, minimizing your downstream development and validation efforts.

FAQ

Q: What exactly does "TOTAL Antibody recognized" mean for an anti-ID Ab?
A: This designation signifies that the anti-ID Ab is meticulously engineered to bind to your antibody drug regardless of its binding state: unbound (free), partially bound to its biological target, or fully complexed with its target. Essentially, it provides a comprehensive measurement of all circulating forms of the drug, which is absolutely crucial for understanding its overall exposure and disposition within a physiological system.
Q: How do these "TOTAL" anti-ID Abs differ from other types?
A: Unlike antigen-blocking anti-ID Abs, which inherently compete with the drug's target antigen for binding, our "TOTAL" recognizing antibodies possess a unique characteristic. They bind to an epitope located specifically outside the drug's antigen-binding site, ensuring this non-blocking interaction does not interfere with the antibody drug's primary function of binding to its biological target, allowing for unobstructed measurement.
Q: Why is measuring "total" drug concentration important in pharmacokinetic (PK) studies?
A: Measuring total drug concentration offers the most complete and accurate understanding of an antibody drug's exposure within a physiological system. This comprehensive data accounts for all circulating forms of the drug, providing critical insights necessary for accurate dose determination, assessing drug clearance mechanisms, and establishing robust correlations between drug exposure and observed clinical efficacy, particularly where target-mediated drug disposition plays a role.
Q: Can these anti-ID Abs be used in ADA assays?
A: Absolutely. Our "TOTAL" recognizing anti-ID Abs are exceptionally valuable as indispensable positive controls and highly reliable reference standards in ADA assays. Their inherent ability to effectively mimic patient-derived anti-drug antibodies, irrespective of the antibody drug's binding state, significantly enhances the robustness and accuracy of your vital immunogenicity assessments throughout development.
Q: What platforms or technologies do you utilize for discovering these antibodies?
A: We primarily leverage cutting-edge in vitro discovery platforms, most notably advanced phage display technology, for the generation of these specialized antibodies. This sophisticated approach enables highly controlled and exceptionally efficient screening processes, allowing us to precisely isolate anti-ID Abs that exhibit the exact binding characteristics required for accurate total antibody recognition.
Q: How do you ensure the specificity and minimize cross-reactivity of the anti-ID Abs?
A: Our rigorous discovery workflow incorporates sophisticated competitive selection strategies coupled with extensive counter-screening steps. We meticulously screen against various endogenous human immunoglobulins and isotype controls to guarantee that the generated anti-ID Abs bind with exquisite specificity exclusively to your antibody drug, exhibiting minimal or no non-specific interactions.
Q: What kind of antibody drugs can your service generate anti-ID Abs against?
A: Our service is remarkably adaptable and possesses the capability to generate "TOTAL" recognized anti-ID Abs against a broad and diverse array of therapeutic modalities. This extensive range includes conventional monoclonal antibodies (mAbs), complex bispecific antibodies, advanced ADCs, and various intricate fusion proteins, among other biotherapeutics.
Q: How can your service benefit my regulatory submissions?
A: The inherently high quality and thorough characterization of our "TOTAL" recognized anti-ID Abs provide exceptionally robust and reliable data that directly supports the bioanalytical sections of your regulatory filings. Utilizing such well-validated and highly specific reagents significantly enhances the credibility and increases the likelihood of acceptance of your critical pharmacokinetic and immunogenicity data by regulatory authorities worldwide.

Creative Biolabs provides you with high-level anti-idiotypic antibody production services for detecting TOTAL antibodies. We have first-class technology and rich experience to help you develop antibody drugs.

Reference

Bulashev, Aitbay K., et al. "Development of an ELISA using anti-idiotypic antibody for diagnosis of opisthorchiasis." Folia Parasitol (Praha) 63 (2016): 025. Distributed under Open Access license CC BY 4.0 , without modification.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: